Laboratory%20Scientist_edited.jpg

IN THE PRESS

 

FZ002 R&D IS PUBLISHED IN TOP JOURNAL

10/28/2020

Research on FZata's leading drug candidate, FZ002, was published in Science Translational Medicine (2020 Oct 28;12(567)).
This break through study was reported by many journals, including Science magazine (https://www.sciencemag.org/news/2020/10/antibody-producing-yeast-vanquishes-deadly-gut-infection-mice), Medical Press (https://medicalxpress.com/news/2020-10-yeast-common-bacterial-intestinal-infection.html), BiotechScope (https://biotechscope.com/antibody-secreting-yeast-immunotherapy-to-treat-deadly-gut-infection/) etc.

FullSizeRender 4.jpg






FZATA WINS NIH SBIR FAST-TRACK GRANT

07/20/2020

FZata wins NIH SBIR Fast-track grant to support the development of FZ002.






FZATA IS SPOTLIGHTED BY EAGB

March 1, 2020

EAGB selected FZata as their Industry Spotlight: Life Science company. 
(https://www.greaterbaltimore.org/news/blog/thriving-against-odds-life-sciences-industry)

IMG_6419.JPG





FZATA, INC. WINS 3RD SBIR FUND

01/20/2018

FZata is awarded an SBIR grant to support the development of a novel companion diagnostic assay for C. diff infection





FZATA WINS 2ND SBIR FUND

01/15/2018

FZata receives an SBIR Phase I grant to support the development of a novel immunotherapy against comorbidity of C. diff infection and Inflammatory Bowel Disease






FZATA WINS  NIH R01 GRANT

March 1, 2017

FZata is awarded an NIH R01 grant to support the development of a novel multi- specific antibody against C. diff infection.





FZATA IS HONORED "2017 MARYLAND INCUBATOR COMPANY OF THE YEAR: BEST LIFE SCIENCE COMPANY"

06/15/2017

It's our great honor to be selected as the Maryland best life science incubator company!

(https://technical.ly/baltimore/2017/06/16/maryland-incubator-company-2017/)

(https://news.umbc.edu/2017-maryland-incubator-company-of-the-year-awards-recognize-three-bwtechumbc-startups/)

trophy.jpeg





FZATA, INC. WINS ITS FIRST SBIR GRANT

01/01/2017

FZata is awarded a SBIR Phase I grant from NIAID to support the study of a novel oral immuo-therapy against C. diff infection.

​As NIH grant awardee, FZata will strictly follow the NIH policy on Financial Conflict of Interest. 

Screen%20Shot%202021-04-08%20at%2010.43_edited.jpg

©2021 by FZata, Inc..